98 related articles for article (PubMed ID: 7615005)
1. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the anti-p53 antibody response in cancer patients.
Labrecque S; Naor N; Thomson D; Matlashewski G
Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
[TBL] [Abstract][Full Text] [Related]
3. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
4. [P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer].
Soussi T; Peyrat JP; Lubin R; Bonneterre J
Pathol Biol (Paris); 1996 Apr; 44(4):232-4. PubMed ID: 8763583
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
6. Wildtype p53-specific antibody and T-cell responses in cancer patients.
Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.
Gnjatic S; Cai Z; Viguier M; Chouaib S; Guillet JG; Choppin J
J Immunol; 1998 Jan; 160(1):328-33. PubMed ID: 9551988
[TBL] [Abstract][Full Text] [Related]
8. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.
Schlichtholz B; Legros Y; Gillet D; Gaillard C; Marty M; Lane D; Calvo F; Soussi T
Cancer Res; 1992 Nov; 52(22):6380-4. PubMed ID: 1423285
[TBL] [Abstract][Full Text] [Related]
9. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
10. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Oncogene; 1997 Jan; 14(4):499-506. PubMed ID: 9053847
[TBL] [Abstract][Full Text] [Related]
11. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
[TBL] [Abstract][Full Text] [Related]
12. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
Sørensen RB; Andersen RS; Svane IM; Engell-Noerregaard L; Hadrup SR; Balslev E; Andersen MH; thor Straten P
Clin Cancer Res; 2009 Mar; 15(5):1543-9. PubMed ID: 19223507
[TBL] [Abstract][Full Text] [Related]
13. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
14. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM; Kerns BJ; Iglehart JD; Marks JR
Cancer Res; 1991 May; 51(10):2605-10. PubMed ID: 1850660
[TBL] [Abstract][Full Text] [Related]
16. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.
Matozaki T; Sakamoto C; Suzuki T; Matsuda K; Uchida T; Nakano O; Wada K; Nishisaki H; Konda Y; Nagao M
Cancer Res; 1992 Aug; 52(16):4335-41. PubMed ID: 1322785
[TBL] [Abstract][Full Text] [Related]
18. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
[TBL] [Abstract][Full Text] [Related]
19. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.
Negrini M; Sabbioni S; Haldar S; Possati L; Castagnoli A; Corallini A; Barbanti-Brodano G; Croce CM
Cancer Res; 1994 Apr; 54(7):1818-24. PubMed ID: 8137297
[TBL] [Abstract][Full Text] [Related]
20. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]